Document Detail

A single-institution retrospective cases series of childhood undifferentiated embryonal liver sarcoma (UELS): success of combined therapy and the use of orthotopic liver transplant.
MedLine Citation:
PMID:  23138115     Owner:  NLM     Status:  MEDLINE    
BACKGROUND/INTRODUCTION: Undifferentiated embryonal liver sarcoma (UELS) makes up 9% to 15% of all malignant liver tumors in children. UELS is characteristically diagnosed between the ages of 6 and 10 years and presents with abdominal pain, vomiting, and an abdominal mass. There is currently no standardized treatment for UELS except attempt at complete surgical resection. There have been only about 150 cases of UELS reported in the literature all with historically poor overall survival of <37.5% at 5 years. This report is one of the largest single-institution reports of UELS consisting of 5 patients over 2 decades. The purpose of this study is to characterize presentation and to report treatment success in UELS in children, adolescents, and young adults and the use of liver transplantation and, lastly, to suggest a use of positron emission tomography/computed tomography (PET/CT) in monitoring of this disease process.
METHODS: We conducted an Institutional Review Board-approved retrospective chart review. Data were collected from UELS patients younger than 21 years seen at the University of California Los Angeles over the past 20 years (January 2001 to September 2011). Descriptive analysis was conducted including multiple parameters of patient demographics, tumor characteristics, treatment modalities, and morbidity and mortality.
RESULTS: Five patients with UELS were identified. Patients initially presented with fever, abdominal pain, or nausea. Ages ranged from 10 to 19 years old (median age 13 y old), and there was a 4:1 male-to-female predominance. Tumor size ranged from 6 to 22 cm in largest diameter. One patient presented with metastatic disease to the lungs and heart and 1 patient recurred 2 years from diagnosis with bilateral paraspinal masses. Treatment included local control surgery with neoadjuvant and adjuvant chemotherapy with an anthracycline/alkylating agent combination. One patient with recurrent and refractory disease achieved local control with an orthotopic liver transplantation (OLT). Metastatic disease was controlled with surgery and radiation therapy. 18-Fluorodeoxyglucose PET/CT was a useful imaging tool for judging response to therapy with complete loss of metabolic activity in tumor after neoadjuvant chemotherapy in 2 representative cases. Although follow-up is short for some patients, overall survival in these 5 patients was 100% with follow-up ranging from 21 to 68 months. Disease-free survival ranged from 8 to 46 months with no patients with residual disease.
CONCLUSIONS: UELS is an aggressive high-grade primary liver sarcoma with high metastatic potential. This report represents one of the largest single-institution studies of UELS. Using multimodality therapy, patients have achieved 100% overall survival even in the setting of extensive disease, metastases, and recurrence. In cases of unresectable primary tumor or recurrent and refractory disease isolated to the liver, OLT is a potential therapeutic option. We report success with adjuvant chemotherapy and complete surgical resection with OLT as an alternative in unresectable or refractory cases. We also suggest a possible utility of PET/CT in monitoring treatment response in this disease.
Ashley S Plant; Ronald W Busuttil; Abbas Rana; Scott D Nelson; Martin Auerbach; Noah C Federman
Related Documents :
20668005 - Cd8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastat...
19052265 - Targeting metastatic melanoma.
16575415 - Identification of circulating malignant cells and its correlation with prognostic facto...
18317795 - Surgery and adjuvant therapies in the treatment of stage iv melanoma: our experience in...
16479065 - Comparison of the efficacy of oral capecitabine versus bolus 5-fu in preoperative radio...
12495285 - Intermediate-dose (25mg/m2) iv melphalan for multiple myeloma with renal failure.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of pediatric hematology/oncology     Volume:  35     ISSN:  1536-3678     ISO Abbreviation:  J. Pediatr. Hematol. Oncol.     Publication Date:  2013 Aug 
Date Detail:
Created Date:  2013-07-26     Completed Date:  2013-09-24     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  9505928     Medline TA:  J Pediatr Hematol Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  451-5     Citation Subset:  IM    
Department of Pediatrics, Division of Hematology/Oncology, Ahmanson Biological Imaging Center/Nuclear Medicine ∥The UCLA Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, Los Angeles, CA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / therapeutic use
Combined Modality Therapy
Liver Neoplasms / mortality,  radionuclide imaging*,  therapy*
Liver Transplantation*
Positron-Emission Tomography and Computed Tomography
Retrospective Studies
Sarcoma / mortality,  radionuclide imaging,  therapy*
Young Adult
Reg. No./Substance:
0/Antineoplastic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  6-Mercaptopurine-induced Recurrent Acute Pancreatitis in Children With Acute Lymphoblastic Leukemia/...
Next Document:  Brain is Not Always the Last Fortress; Osteosarcoma With Large Brain Metastasis.